上皮性卵巢癌残留病灶与生存的关联因组织学类型而异
基于美国国家癌症数据库2011至2013年数据,回顾性队列纳入IIIC或IV期上皮性卵巢癌患者,其中高级别浆液性6013例、透明细胞307例、黏液性140例,比较无残留病灶、≤1cm和>1cm残留与全因死亡风险的关联。结果显示残留病灶与死亡风险的关联在各组织学亚型间无显著差异(交互作用P=0.32),无肉眼残留病灶相较于不满意减瘤在高级别浆液性癌中HR=0.58(95%CI 0.49-0.68),透明细胞癌HR=0.39(95%CI 0.22-0.69),黏液性癌HR=0.46(95%CI 0.22-0.99)。
要点
- 残留病灶状态与死亡风险的关联在卵巢癌各组织学亚型间无显著差异(交互作用P=0.32)。
- 无肉眼残留病灶相较于不满意减瘤,高级别浆液性癌死亡风险HR=0.58(95%CI 0.49-0.68)。
- 无肉眼残留病灶相较于不满意减瘤,透明细胞癌HR=0.39(95%CI 0.22-0.69),黏液性癌HR=0.46(95%CI 0.22-0.99)。
核心结论
- 未发现手术减瘤在高级别浆液性癌中比化疗反应较差的组织学类型具有更大预后重要性的证据。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2011至2013年数据,纳入接受初次减瘤手术和辅助化疗的IIIC或IV期上皮性卵巢癌患者。
- 样本包括高级别浆液性癌6013例、透明细胞癌307例、黏液性癌140例;因26%样本残留病灶状态未知,主要分析采用多重插补。
主要发现
- 残留病灶状态与死亡风险的关联在各组织学亚型间无显著差异(交互作用P=0.32)。
- 协变量校正模型中,相较于不满意减瘤,无肉眼残留病灶在高级别浆液性癌中与死亡风险降低42%相关(HR=0.58,95%CI 0.49-0.68)。
- 无肉眼残留病灶在透明细胞癌中与死亡风险降低61%相关(HR=0.39,95%CI 0.22-0.69),在黏液性癌中与死亡风险降低54%相关(HR=0.46,95%CI 0.22-0.99)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Surgical cytoreduction has been postulated to affect survival by increasing the efficacy of chemotherapy in ovarian cancer. We hypothesized that women with high-grade serous ovarian cancer, which usually responds to chemotherapy, would derive greater benefit from complete cytoreduction than those with histologic subtypes that are less responsive to chemotherapy, such as mucinous and clear cell carcinoma. METHODS: We conducted a retrospective cohort study of patients who underwent primary cytoreductive surgery and adjuvant chemotherapy for stage IIIC or IV epithelial ovarian cancer from 2011 to 2013 using data from the National Cancer Database. We constructed multivariable models to quantify the magnitude of associations between residual disease status (no residual disease, ≤1cm, or >1cm) and all-cause mortality by histologic type among women with clear cell, mucinous, and high-grade serous ovarian cancer. Because 26% of the sample had unknown residual disease status, we used multiple imputations in the primary analysis. RESULTS: We identified 6,013 women with stage IIIC and IV high-grade serous, 307 with clear cell, and 140 with mucinous histology. The association between residual disease status and mortality hazard did not differ significantly among histologic subtypes of ovarian cancer (p for interaction=0.32). In covariate adjusted models, compared to suboptimal cytoreduction, cytoreduction to no gross disease was associated with a hazard reduction of 42% in high-grade serous carcinoma (hazard ratio [HR]=0.58, 95% confidence interval [CI]=0.49-0.68), 61% in clear cell carcinoma (HR=0.39, 95% CI=0.22-0.69), and 54% in mucinous carcinoma (HR=0.46, 95% CI=0.22-0.99). CONCLUSIONS: We found no evidence that surgical cytoreduction was of greater prognostic importance in high-grade serous carcinomas than in histologies that are less responsive to chemotherapy.
引用
- Melamed A, Manning-Geist B, Bregar AJ, et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecol Oncol. 2017. PMID: 28822556. doi:10.1016/j.ygyno.2017.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。